Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents

How to Cite This Article: Fallah E, Arman A, Najafi M, Shayegh B. Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents. Iran J Child Neurol. Spring 2016; 10(2):16-25.

Abstract

Objective

Many studies have supported the role of protein kinase C (PKC) inhibitors in the physiopathology and treatment of bipolar disorder in adults. Tamoxifen is one of the drugs with the effect of PKC inhibition. This study aimed to determine the effect of tamoxifen on the rate of improvement mania symptoms in the sample of children and adolescents with acute mania.

Materials & Methods

In this randomized, placebo-controlled clinical trial study, registered in www.irct.ir with the code of IRCT201410126418N3, overall 44 patients with bipolar disorder with acute manic episode were randomly assigned into treatment and control groups. The serum levels of lithium and tamoxifen among the participants in the treatment groups were 0.8 -1.1 mg and 20-40 mg per day respectively. Serum level of lithium among participants in the control group was similar. The main comparisons were made based on the Young Mania Rating Scale (YMRS) and Children Depression Inventory (CDI) scores of the participants at baseline and at the end of each study week. The pharmacological side effects of serum level of lithium were examined weekly. Analysis of Covariance (ANCOVA) test was used for the statistical analysis.

Results

There was no difference in the baseline score of YMRS and CDI in the treatment and control groups while a statistical significant difference (P < 0.05) in these scores was found between and within the groups.

Conclusion

The addition of tamoxifen to lithium causes a significant difference in reducing the symptoms of mania and depression in the treatment group compared to the control group.

Keywords: Lithium; Mania; Protein Kinase C; Tamoxifen; Children

Introduction

The identification of protein kinase C (PKC) has recently been introduced as a promising therapeutic aim. Protein kinase C is a large family of isoenzymes typically found in brain and plays a crucial role in settings before and after synapse called neurotransmitter. PKC facilitates the release of dopamine (1). Regulation of long-term changes in gene and neuronal plasticity is another important role of PKC (2, 3). The pathway of PKC signals regulates the morphology of dendritic branches (4).
PKC activity and change in platelets of patients with mood disorder is in response to protein, which increases the percentage of response in patients with mania, besides it is reduced in patients treated by lithium (5). In rodents, PKC stimulation caused by cocaine stimulus makes the excitation of manic symptoms. On the other hand, the inhibition of PKC activity by lithium and valproate results in the reversal of the manic symptoms (6, 7). Amphetamines create manic-like behaviors in rodents through the effect on PKC and phosphorylation of GAP.43 (playing a role in the release of dopamine neurotransmitter) (8-10). The use of lithium, valproate and tamoxifen inhibit the increase of amphetamine-induced activity (11).

Since the late 1990s, some drugs have been made based on the activity of PKC inhibition, while the mandatory characters to test such drugs in humans include: having the ability for PKC inhibition in areas of the brain involved in the mood disorder, evaluating this ability in more than an animal model, passing easily from Blood-Brain Barrier (BBB) and tolerating the drug absorption. The best acceptable candidate with PKC inhibitory feature that meets the above characters is Tamoxifen (12). Tamoxifen is a synthetic anti-estrogen drug used for the treatment of breast cancer (12) and the prevention of osteoporosis (13). Due to the lack of metabolic and neurological side effects, compared to antipsychotic drugs, it is a good alternative in the treatment of acute mania (14). Drugs recognized to have interact with tamoxifen are 2D6 and P150 drugs such as paroxetine, sertraline and duloxetine (15) and sodium valproate, Plus phenytoin and carbamazepine (16). Early and before maturity onset of a bipolar disorder, usually becomes chronic and appears without specific periods and with high rate of mixed mania (17). The disease is comorbid in onset, worsened by other group of disorders (18) and at an increasing rate of comorbidity (19). Therefore, an appropriate, timely, effective and low risk treatment is essential for bipolar disorder in children. However, there are a few drug-controlled studies in this field (20). Short-term studies on clinical samples in America showed that early-onset of Bipolar I disorder is associated with slow response rate to treatment, persistent mood swings, high recurrence rate, high risk of attempted suicide and severe psychosocial disorders (21). Therefore, an aggressive treatment of mania and prevention of manic episodes can minimize the risk of manic-depressive disorders (22). However, intolerance to some side effects such as metabolic disorders and overweight are other problems that require a special attention and cause some limitations to use of these drugs (23). Prevention of recurrence plays an important role in the treatment of bipolar disorder. The primary objective of recent advanced treatment methods is control of the acute phase of the disorder before advancing into the chronic stage. This objective can be achieved by the use of available anti-mania, antipsychotic and anticonvulsants drugs. With the exception of lithium, these three categories of drugs have no priority one over the other (24). Furthermore, no interaction has been reported between tamoxifen and lithium (25). Anti-manic drugs such as lithium and valproate have influence over PKC (26).

There are some reports concerning the effect of tamoxifen in treating bipolar disorder in adults. However, there was no controlled study to evaluate the effect of tamoxifen in children and adolescents with bipolar disorder (8, 27). Studies on children who suffered from desmoid fibromatosis gynecomastia (27) and low-grade brain gliomas (28) and who were on tamoxifen therapy up two years reported no serious complications. This has paramount importance because similar drugs with appropriate doses that are used in adults can work for children and adolescents (29). Thus, prompt treatment of manic episodes and preventing the occurrence of chronic course of the disorder and possible side effects of some anti-manic drugs such as valporates and second generation, antipsychotics starting from childhood is vital.

This study was aimed at measuring the effect of tamoxifen as an adjuvant of lithium in reducing the rate of symptoms of mania in children as well as adolescents with mood disorder.

Materials & Methods

This randomized, double-blinded clinical trial registered in www.irct.ir with the code of IRCT201410126418N3, was conducted on nine to 20 yr old patients with the diagnosis of acute mania hospitalized at Al-Zahra University Hospital-Psychiatric Ward, Isfahan, Iran. The total sample size was 44 patients of which 22 were
assigned in the treatment group (receiving tamoxifen + lithium) and the remaining 22 in the control group (receiving placebo + lithium).

Written consent was obtained from the guardian or parent of each patient after explaining the methods and aims of the performance. In addition, the therapeutic method was verbally explained the study participants based on their level of understanding and developmental stage. This study has been approved by ethical committee of Isfahan University of Medical Sciences with the code of 393501.

The inclusion criteria for the study subjects were the age range of 9-20 yr old, the diagnosis of bipolar disorder based on K-SADS interview, the Young Mania Rating Scale (YMRS) score of above 20, cutting or not taking any medication that can affect the mind for at least 2 weeks prior to the study, independence from any narcotic and psychotropic drugs for one month before the study had begun, IQ score of greater than 70 and no major nervous and physical diseases such as epilepsy.

Lack of desire to continue in the study and the creation of intolerable side effects were the exclusion criteria.

**Instruments for data collection:**

1. The questionnaire of demographic characteristics including age and education level
2. K-SADS Semi-structured interview
   Diagnosis of the bipolar disorder, schizophrenia, and its type and episode was performed prior to treatment using K-SADS interview. The reliability and validity of the Persian version for assessment and diagnosis of psychiatric disorders in children have been reported as accepted (30).
3. The questionnaire of Young Mania Rating Score (YMRS) is a measure filled by a physician after interviewing a patient, parents and if possible, employees in the psychiatric ward. This questionnaire is made up of 11 items which are scored in 4 levels and for each level a definition for that item has been provided. The scores ranged from zero to 6. The reliability of the test has been reported in the range of 0.41 to 0.85 and its validity is 0.89 compared to the Patterson Mania and 0.88 compared to the Total Mania Rating Tests. The cut-off point for diagnosing manic disorder is a score of above 20. This test enables to differentiate bipolar disorder from Attention Deficit-Hyperactivity Disorder (ADHD) and is to some extent sensitive to treatment with mood stabilizers (31).
4. Maria Kovacs’s Child Depression Inventory (CDI): is like Beck’s Depression inventory and is leveled as zero, 1 and 2. The range of scores is from zero to 54 and the cut-off and diagnosis point of depressed patients is a score of more than 20. In order to measure the validity, Concurrent validity measure of CDI scale by teachers has shown a score of 0.193, which was significant (32).
5. Table of side effects (33)

   Somnolence during day, morning Somnolence, constipation, dizziness, fatigue, restlessness, tremor, increasing appetite, loss of appetite, blurred vision, diarrhea, dry mouth, nervousness

Based on randomized blocks, patients were divided into two equal groups that placebo + lithium was administered to one group, while tamoxifen + lithium were administered to the other group. The study subjects were given 300 mg dose of lithium on the first day. Based on the patient’s tolerance level and weekly monitoring for its serum level, the dose was increased to 0.8-1.1 mg/l. Again, tamoxifen was started with daily standard-dose for children, about 20 mg, and increased to a maximum of 40 mg/d (33).

Patients of developed insomnia or agitation were managed with lorazepam at a starting dose of 1 mg to 4 mg for the first four days of hospitalization and then, the dose for the following days was reduced to 2 mg. Placebo, made up of sucrose, was started alone once a day in the control group receiving lithium and it was increased to twice a day. The questionnaires for YMRS, CDI and drug side effects were filled before intervention and in the first, second and third weeks.

Response to treatment was evaluated at 50% reduction in the rate of YMRS (30), using SPSS version 18 (Chicago, IL, USA). Age and sex were controlled for the ANCOVA and the changes in the CDI and YMRS scores in the first, second and third weeks of study were compared between the intervention and control groups.

**Results**

Figure 1 shows the trend of estimated marginal means
over the follow-up period of the study. Initially, the basic assessments were completed using YMRS and CDI questionnaire for 65 study participants. The subjects were randomly assigned to the treatment group (tamoxifen with lithium) or control group (placebo with lithium) and were followed for three weeks. There was no statistically significant difference in age, sex, and education level at baseline of the two groups. The mean age of the participants in the tamoxifen-lithium group was 13.8 yr with standard deviation (SD) of ± 2.1 yr and that of the placebo-lithium group was 14.5 ± 1.9 SD yr. From 10 (45.5%) males and 12 (54.5%) females there were 4 patients in the group receiving tamoxifen and from 7 males and 15 females, 8 in the group receiving placebo that were excluded from the study due to severe aggressive behaviors, aggressive and serious suicidal thoughts and refusal to eat. Therefore, Electro Convulsive Therapy (ECT) was started for them. From participants 8 patients were excluded due to lack of cooperation on taking drug and finally, 44 children (17 males and 27 females) stayed in the plan. At the beginning of the study, all the participants had the YMRS score of above 20. While on the CDI score, 55% of the patients had score of less than 20. That means the patients who participated in the study were composed of those having acute and mixed stages of mania. There was no statistically significant difference in YMRS score at baseline between the two groups. Because there was a significant difference in CDI score among the participants at baseline, the role of CDI score was controlled in the analysis. At the end of the first, second and third weeks of the study, there were statistically significant (P <0.05) differences within YMRS and CDI groups and statistically significant (P <0.05) differences between the treatment and control groups (Table 1).

The effect of follow-up time in four steps (at baseline and the first, second and third weeks), the difference between the intervention and control groups and in addition to the interaction between these two groups with the follow-up period is summarized in Table 2. There was no statistically significant difference (F3 and 39 = 2.4; P = 0.81) between follow-up periods (follow-up periods at baseline and at the end of first, second and third weeks). However, there was a statistically significant difference (F1 and 41 = 3.4; P=0.001) between the treatment (tamoxifen + lithium) and the control (placebo+ lithium) groups (Figure 1, 2).

**Fig 1.** Covariates appearing in the model are evaluated at the following values: Age=14.5±1.9 (yr)

With regard to Table 3, there was no statistically significant difference (F3 and 39 = 0.602; P= 0.67) between follow-up periods, while a significant difference (F1 and 41= 26.6; P = 0.001) was identified between the intervention and control groups.

**Fig 2.** Covariates appearing in the model are evaluated at the following values:

Age=14.5±1.9 (yr)
The mean differences in YMRS scores in the treatment and control groups between baseline and end of the first week, between ends of the first and the second weeks and ends of the second and the third weeks were 8.5, 5.3 and 3.9, respectively. After the first week, 10 (45.5%) participants in the treatment group and 2 (9.1%) among the control group, showed 50% reduction in YMRS score and there was a statistically significant difference (P = 0.007) between these two groups. At the end of the second week, the YMRS score of 19 (86.4%) of participants in the treatment group and 7 (31.8%) of participants in the control group was less than 50% and the difference in these scores was statistically significant (P = 0.001). Besides, of 22 (100%) participants in the treatment group and 12 (54.5%) in the control group had less than 50% reduction in YMRS at the end of the third week. This difference was statistically significant (P < 0.001).

In addition, the mean difference in CDI score between the treatment and control groups at baseline and the end of the first week, the CDI score of 19 (86.4%) of patients in the treatment group and 12 (54.5%) in the control group had less than 50% reduction in YMRS scores at the end of the third week. The symptom of mania among the treatment group was significantly controlled while the symptoms of depression were not significantly controlled. In the control group, there was no significant difference between YMRS and CDI scores in the follow-up period. Out of the 13 participants who developed side effects, eight of them were from the control group while only two participants in the treatment group developed side effects. The remaining three participants reported to have developed dry mouth and more of them were in from the treatment group. Generally, a statistically significant difference (P = 0.009) in relation to side effect development was observed between the treatment and control groups.

Discussion
In this clinical trial, the addition of tamoxifen to lithium resulted in an increased rate of clinical improvement, especially in the first week of treatment. A significant decrease in YMRS and slight decline in CDI scores were observed.

Treatment with 40 mg tamoxifen per day is well tolerated in children and there were no serious side effects and complications observed except dry mouth. The efficiency of tamoxifen in reducing manic symptoms in this study supports the hypothesis that PKC plays a great role in the treatment of mania. The effects of tamoxifen on central nervous system are complex and appear to be a serotonergic system antagonist. However, it has no stimulatory effects in cholinergic and adrenergic systems (31, 32).

In another study, maniac symptoms were created in mice by injecting amphetamine in which the symptoms were controlled through injecting tamoxifen for 14 days and it seemed that tamoxifen had controlled dysfunction in hippocampus and frontal area (33). The use of tamoxifen in Kun- Albright syndrome in children has been approved (34). In a study on 7 boys with precocious puberty treated by tamoxifen with the dose of 10-20 mg for 2 years, no side effect was reported (35).

Another study conducted on 59 patients aged between 10-18 yr with desmoid fibromatosis treated with a high dose of tamoxifen for two years helped to control the underlying diseases and reported no specific side effects (36). In a study on 38 adolescents with gynecomastia of puberty period at the age group of 14.6 years treated by tamoxifen with the dose of 40 mg for 3 and 9 months, no specific side effects were reported; however, the underlying disease was controlled (37). In a study on 14 children under 14 year-old with the diagnosis of low-grade brain gliomas treated by tamoxifen with the dose of 20 mg for one year, it operated well without specific side complication in the control of gliomas (38). In 5 studies on adults, the effect of tamoxifen in the decrease of symptoms of mania was is consistent with our results; however, no study was found on the effect of tamoxifen on the mood of children. In a single blind study on 7 subjects in the age group of 18-65 yr old (5 females and 2 males), tamoxifen could have a good performance in the treatment of acute mania (39). Tamoxifen only with the dose of 20-40 mg was tolerated for 15 days well (39). The anti-mania effect of tamoxifen on 51 women was compared with that of medroxy progesterone acetate for 4 weeks and the anti-mania effect of tamoxifen with the dose of 80 mg per day was not attributed to its anti-estrogenic effects, and it was resulted from the blocks of receptors of protein kinase C (40). In another study for 35.4±7.8 years old participants (41) and in the study on the age group of 18-65 yr old (42), as monotherapy with
a high dose (140 mg per day (40) and 80 mg per day (41), tamoxifen was used to treat patients with bipolar disorder by current or mixed mania episode for three weeks. They also evaluated the effect of tamoxifen on other symptoms such as depression and psychosis. Both above-mentioned studies showed the high ability of tamoxifen as a potent inhibitor of PKC to improve the symptoms of mania in which the psychotic symptoms was controlled too (41, 42). However, in Hamilton Rating Scale for Depression (HRSD), there was no significant change in comparison with placebo (41, 42). The combined treatment of lithium with tamoxifen led to a clear mood stability and even the control of symptoms of psychosis in bipolar disorder (43). In the present study, maximum recovery time and reduction in YMRS score were observed in the first week. In addition, in the mixed stage of mania cases, CDI score was dropped by controlling the underlying disease. In none of the participants in treatment group, depression was not developed following the use of tamoxifen and this is consistent with the findings of studies on adult patients with bipolar disorder or current or mixed mania episode (40, 43).

The development of depression symptoms were usually reported following the long-term use of tamoxifen and in patients who had an innate potential to depression (44). In a study on 2943 patients with breast cancer treated by prolonged monotherapy with tamoxifen with the dose of 80 mg, the incidence of New-onset depression in tamoxifen recipients was not significant (45). However, it seems that a short-term treatment (three weeks) with the low-dose of tamoxifen in patients with bipolar disorder not only causes the induction of depression but also controls the symptoms of depression in the mixed cases through the control of acute symptoms of the disease (24).

No subject left the study due to the side effects of the drug and only dry mouth in the tamoxifen group was more common than that in the placebo group. The present study is pioneer in the investigation of the effect of tamoxifen, which showed the effect on acute phase of the disorder is consistent with the similar results of the disorder in adults (20, 22, 38, 40).

In conclusion, the addition of tamoxifen to lithium showed a significant difference between the treatment and control groups in reducing the symptoms of mania and depression.

Acknowledgements
We express gratitude to all of the Department faculty members for their sincere cooperation. This manuscript was supported financially by Isfahan University of Medical Sciences.

Authors’ contribution
Elham Fallah: Acquisition, analysis and interpretation
Sorror Arman: design of the work,
Mostafa Najafi: Drafting the work and revising it critically for important intellectual content
Bahar Shayegh: acquisition

Conflict of Interest: There was no conflict of interest.
**Table 1.** Within group comparison of CDI and YMRS scores at baseline and at the end of first, second and third weeks of follow up the study participants with bipolar disorder treated by tamoxifen or placebo

| Variable | Tamoxifen-Lithium | Lithium-Placebo | P. Value |
|----------|-------------------|-----------------|----------|
| Mean of YMRS* SD-(Base) | 24.5±5.4 | 7±28 | 0.094 |
| Mean of CDI# SD-(Base) | 13±6.5 | 11±23 | <0.001 |
| Mean of YMRS SD-(First Week) | 6±13 | 7±23 | <0.001 |
| Mean of CDI SD-(First Week) | 5±15 | 18.5±10.5 | <0.002 |
| Mean of YMRS SD-(Second Week) | 6.4±7 | 8±18 | <0.0001 |
| Mean of CDI SD-(Second Week) | 4±8 | 9±17 | <0.0001 |
| Mean of YMRS SD-(Third Week) | 3.5±3 | 9±14 | <0.0001 |
| Mean of CDI SD-(Third Week) | 4±6 | 7±16 | <0.0001 |

*Young Mania Rating Scale (YMRS), # Children Depression Inventory

**Table 2.** Results of covariance with replicated test score with the result of mania score in the study population controlling age and sex

| Variables | F value | DF | P. value |
|-----------|---------|----|----------|
| Follow up duration | 2.42 | 3.37 | 0.081 |
| Intervention Group (Lithium+Tamoxifen/Lithium+Placebo) | 3.42 | 1.39 | 0.001 |
| The interaction of follow up duration and intervention groups | 3.25 | 3.37 | 0.032 |

**Table 3.** Results of the analysis of covariance (ANCOVA) with replication with the outcome of depression score in the population studied controlling age and sex

| Variables | F value | DF | P. value |
|-----------|---------|----|----------|
| Follow up duration | 0.602 | 3.39 | 0.617 |
| Intervention Group (Lithium+Tamoxifen/Lithium+Placebo) | 26.6 | 1.41 | 0.001 |
| The interaction of follow up duration and intervention groups | 0.592 | 3.39 | 0.624 |
Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms

Table 4. Comparison of side effects in the two studied groups

| Side Effect         | Lithium+Tamoxifen | Lithium+Placebo | P. value |
|---------------------|-------------------|-----------------|----------|
| Drowsiness          | 0.22              | 2.22            | 0.488    |
| Vertigo             | 0.22              | 2.22            | 0.488    |
| Shivering           | 1.22              | 4.22            | 0.254    |
| Overeating          | 0.22              | 1.22            | 1        |
| Anorexia            | 0.22              | 2.22            | 0.488    |
| Blurred vision      | 1.22              | 2.22            | 1        |
| Fatigue             | 0.22              | 1.22            | 1        |
| Agitation           | 1.22              | 0.22            | 1        |
| Xerostomia          | 7.22              | 0.22            | 0.009    |
| Anxiety             | 0.22              | 2.22            | 0.488    |
| Diarrhea            | 0.22              | 0.22            | 1        |
| Constipation        | 0.22              | 0.22            | 1        |
| Low body movement   | 0.22              | 0.22            | 1        |

References
1. Manji HK, Lenox RH. Ziskind- Somerfeld Research Award. Protein Kinase C signaling in the brain: Molecular Transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46(10):1328-51.
2. Calabrese B, Halpain S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 2005; 48(1)77-90.
3. Craske ML, Fiveaz M, Batad NN, Meyer T. Spines and neurite branches function as geometric attractors that enhance protein Kinase C action. J Cell Biol 2005; 170(7): 1147-58.
4. Friedman E, Hoan Yan W, Lewinson D, Connell TA, Singh H. Altered Platelet Protein Kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993; 33(7):520-5.
5. Wang Hy, Freidman E. Enhanced Protein Kinase C activity and translation in bipolar affective disorder brain. Biol Psychiatry 1996;40(7)568-75.
6. Einat H, Yuan P, Szaho ST, Dogra S, Manji HK. Protein Kinase C inhibition by tamoxifen antagonizes manic like behavior in rats: Implications for the development of novel therapeutics for bipolar disorders. Neuropsychology 2007: 55(34): 123-31.
7. Harisson-Read PE. Models of mania and antimanic drug actions: Progressing the endophenotype approach. J Psychopharmacol 2008;23(3):334-7.
8. Gimbalvo CT. Protein Kinase C and dopamine transport-2. Effects of amphetamine in Ultro. Neuropharmacology 1992; 31(12): 1211-22.
9. Gimbalor CT. Protein Kinase C and dopamine transport-2. Effects of amphetamine in Ultro. Neuropharmacology 1992; 31(12): 1201-10.
10. Genegy ME, Hong P, Ferell ST. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res
Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms

1. Calabrese B, Halpain S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 2005; 48(1):77-90.
2. Jordan VC. Molecular mechanisms of anti-estrogen action in breast cancer. Breast Cancer Res Treat 1994; 31(1): 41-52.
3. R. Love R. Effects of tamoxifen on Bone Mineral Density in post-menopausal women with breast cancer. N Engl J Med 1992; 326: 1023-28.
4. National Cancer Institute UNIOH, Tamoxifen: Questions and Answers, 2010; 11.
5. Desmaria J. Interaction between tamoxifen and Antidepressants via Cytochrome P4502D6. J Clin Psychiatri 2009; 20(12):1688-1697.
6. Geller B, Craneg JL, Bolhofner K, Nickelsburg MJ, Williams M. Phenomenology and Longitudinal course of children with a prepubertal and early adolescent bipolar disorder phenotype. Bipolar disorder in childhood and early adolescence. Guilford 2003:25-50.
7. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Zarate CA, Singh JB, Carlshn PL, Quiro J, Zolkovsky L, Luckcu Baugh DA, et al. The Stanley foundation bipolar treatment outcome Network: Demographics and illness characteristics at the first 261 patients. J Affect Disord 2001; 67: 45-59.
8. Smarty S, Find ling RL, Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Psychopharmacology of pediatric bipolar disorder: A review. Psychopharmacology 2007; 191: 39-54.
9. Del Bello MP, Findling RL. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J AM Acad Child Adolesc Psychiatry 2005; 44: 539-47.
10. Gabrielle A, Carlson Stephanie E, Meyer C. Early onset bipolar disorder. Test book of Psychiatry, Kaplan and Sadock, 2009: 3663-3670.
11. Sachs GS, Gardner-Schuster EE. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatry Scand Suppl 2007; (434): 27-34.
12. Fagliolini A, Chengappa KN. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007; 9(6): 521-8.
13. Manji HK, Zaratse CA. Molecular and cellular mechanisms underlying mood stabilizations for the development of improved therapeutics. Mol Psychiatry 2002; 7: 51-7.
14. Manji HK, Bebchuk JM, Moore Gj, Glitz D, Hasanat Ka, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: Clin Psychiatry 1999; 60: 27-39.
15. Lawrence SE, Faught KA, Vetham Y, Lawson ML. Beneficial effects of raloxifene and Tamoxifen in the treatment of Pubertal Gynecomastia. J Pediatr 2004; 145: 71-76.
16. Bebchuk JM, Artkan CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein Kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57(1): 95-7.
17. Gould TD, Einat H. Animal models of bipolar disorder and mood stabilize efficacy: a critical head for Improvement. Neurosci Bio Behave Rev 2007; 31(6): 825-31.
18. Karimi S (2009). normalization, reliability, validity and analysis of Coax Depression Inventory questionnaire in students in Secondary school, MA thesis in psychology, Department of Postgraduate education, Islamic Azad University, Khorasgan Branch.
19. Charles F, Armstrong L, Goldman M, Lance L. Drug information Handbook- Tamoxifen. 2013; 1478-1480.
20. Carlson GA. Meyer SE. Bipolar disorder. Textbook of child and adolescent psychiatry Mina K. Dulcan 2010; 280-295.
21. Eueger EA, Rabin SD, Raiter EO. Tamoxifen treatment for precocious puberty in McCune-Albright Syndrom: A multi-center trial. J Pediatr 2003; 143: 60-66.
22. Neriss C, Kreher, Erica A. Eueger and R. Ravi Shankar A, Pediatrics, 2005; 116; 1513.
36. Lawrence SE, Faught KA, Vethamat Y, Lawson ML. Beneficial effects of raloxifene and Tamoxifen in the treatment of Pubertal Gynecomastia. J Pediatr 2004; 145: 71-76.

37. Walter AW, Gajjar A, Reavdon DA. Tamoxifen and cauhoplutin for children with low grade gliomas: A pilot study at St. Jude Children’s Research Hospital. J Pediatr Hematol Oncol 2000; 22: 247-251.

38. Bebchuk JM, Artkan CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein Kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57(1): 95-7.

39. Kullcarni J, Garaland KA, Scaffidi A, Headey B, Anderson R, Castella de A, et al. A pilot study of hormone modulation as a new treatment for manic in women with bipolar affective disorder. Psych-neuroendocrinology 2006; 31(4): 543-7.

40. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Zarate CA, Singh JB, Carslan PJ, Quiroz J, Jolkovsky L, Luckcu Baugh DA, et al. Efficacy of a protein kinase C inhibitor (Tamoxifen) in the treatment of acute mania. A pilot study. Bipolar Disorder 2007; (9) (6): 561-70.

41. Smarty S, Find ling RL, Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Protein Kinase C inhibition in the treatment of manic: a double blind, Placebo controlled of tamoxifen. Arch Gen Psychiatry 2008; 65(3): 255-63.

42. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH Maroufi A, Esfandiari G, et al. Efficacy and safety of the Tamoxifen adjunctive to lithium in acute bipolar mania. J Affec Disord 2011; 327-331.

43. Bebchuk JM. A preliminary investigation of a protein Kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiat 2005; 31(4): 543-547.

44. Kelly C, Lee A. Tamoxifen treatment and New-onset depression in Breast cancer patients. Psychosomatics 2007; 48(3): 205-210.